SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Reduce Stake in IMMUNOME INC to 4.5%

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a reduction in their beneficial ownership stake in IMMUNOME INC to 4.5% as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson jointly reported beneficial ownership of 3,892,318 shares of IMMUNOME INC common stock.
• This represents 4.5% of the total outstanding common stock of IMMUNOME INC.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a change from a previously reported position.
• The date of the event requiring the filing was March 31, 2025.
• FMR LLC, a Delaware-organized entity, holds sole voting power over 3,891,512 shares and sole dispositive power over 3,892,318 shares.
• Abigail P. Johnson, a U.S. citizen, holds sole dispositive power over 3,892,318 shares.
• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the implied reduction in beneficial ownership by a major institutional investor, as indicated by the 4.5% stake in an amendment filing, suggesting a partial divestment from a previous higher holding.

Positives

• A prominent institutional investor, FMR LLC, continues to hold a significant stake in IMMUNOME INC, indicating ongoing investment interest.
• The filing explicitly states that the securities are held in the ordinary course of business and not for the purpose of influencing control, which can provide stability regarding corporate governance.

Negatives

• The reported beneficial ownership of 4.5% is below the 5% threshold that typically triggers an initial Schedule 13G filing, and as an 'Amendment No. 2', it implies a reduction from a previously reported higher stake (likely 5% or more).
• A reduction in a significant institutional holding by a major firm like FMR LLC could be interpreted as a decrease in conviction or a partial divestment, potentially signaling a less favorable outlook.

Risks

• A decrease in beneficial ownership by a major institutional investor such as FMR LLC could negatively influence market sentiment and potentially lead to a decline in IMMUNOME INC's stock price.
• Changes in significant shareholder positions can sometimes contribute to increased stock volatility as other investors react to the news.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the issuer's future performance, strategic direction, or financial estimates, as it is solely an ownership disclosure filing.

Management Comments

• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing represents a routine disclosure of institutional ownership, a common practice within the investment management industry. It indicates that a major asset manager, FMR LLC, continues to hold a significant, though reduced, stake in IMMUNOME INC, a biotechnology company. Such disclosures are standard for large investment firms managing diverse portfolios and provide transparency on significant holdings.

Comparison to Industry Standards

• This Schedule 13G filing adheres to standard regulatory disclosure requirements for institutional investors whose beneficial ownership crosses or changes certain thresholds.
• The reported 4.5% stake is below the 5% threshold for initial Schedule 13G filings, and as an amendment, it suggests a reduction from a previously reported higher stake, which is a common occurrence in institutional portfolio management.
• No specific comparable companies, projects, or results are mentioned in this ownership filing, as its scope is limited to beneficial ownership disclosure.

Related Party Transactions

• Abigail P. Johnson, as a Director, the Chairman, and the Chief Executive Officer of FMR LLC, and a predominant owner of FMR LLC's voting shares, is considered part of the controlling group with respect to FMR LLC. This establishes a related party relationship between the two reporting persons in their beneficial ownership filing.

Stakeholder Impact

• **Shareholders**: The implied reduction in a significant institutional stake might lead to concerns about investor confidence and potentially influence the company's stock price.
• **Company Management**: Awareness of changes in major institutional holdings can inform investor relations strategies and potentially influence future capital allocation decisions.

Next Steps

• The document does not specify any future actions, events, or milestones for the issuer or the reporting persons beyond the ongoing regulatory compliance requirements for beneficial ownership.

Key Dates

Keywords

IMMUNOME INC, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management